SI2193133T1 - Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze - Google Patents

Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze

Info

Publication number
SI2193133T1
SI2193133T1 SI200831527T SI200831527T SI2193133T1 SI 2193133 T1 SI2193133 T1 SI 2193133T1 SI 200831527 T SI200831527 T SI 200831527T SI 200831527 T SI200831527 T SI 200831527T SI 2193133 T1 SI2193133 T1 SI 2193133T1
Authority
SI
Slovenia
Prior art keywords
imidazolothiadiazoles
protein kinase
kinase inhibitors
inhibitors
protein
Prior art date
Application number
SI200831527T
Other languages
English (en)
Slovenian (sl)
Inventor
Paolo Pevarello
Collazo Ana Maria Garcia
Garcia Ana Belen Garcia
Original Assignee
Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii filed Critical Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii
Publication of SI2193133T1 publication Critical patent/SI2193133T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI200831527T 2007-09-27 2008-09-29 Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze SI2193133T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07381066 2007-09-27
PCT/GB2008/003287 WO2009040552A2 (en) 2007-09-27 2008-09-29 Substituted imidazo (2, 1-b) -1, 3, 4-thiazole compounds, their pharmaceutical compositions and uses thereof
EP08806437.3A EP2193133B1 (en) 2007-09-27 2008-09-29 Imidazolothiadiazoles for use as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
SI2193133T1 true SI2193133T1 (sl) 2015-12-31

Family

ID=39092755

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200831527T SI2193133T1 (sl) 2007-09-27 2008-09-29 Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze

Country Status (13)

Country Link
US (1) US8563550B2 (cg-RX-API-DMAC10.html)
EP (1) EP2193133B1 (cg-RX-API-DMAC10.html)
JP (1) JP5410431B2 (cg-RX-API-DMAC10.html)
CN (1) CN101878219B (cg-RX-API-DMAC10.html)
CY (1) CY1116882T1 (cg-RX-API-DMAC10.html)
DK (1) DK2193133T3 (cg-RX-API-DMAC10.html)
ES (1) ES2548768T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20151128T1 (cg-RX-API-DMAC10.html)
HU (1) HUE025976T2 (cg-RX-API-DMAC10.html)
PL (1) PL2193133T3 (cg-RX-API-DMAC10.html)
PT (1) PT2193133E (cg-RX-API-DMAC10.html)
SI (1) SI2193133T1 (cg-RX-API-DMAC10.html)
WO (1) WO2009040552A2 (cg-RX-API-DMAC10.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
PT1912675E (pt) 2005-07-25 2014-05-09 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
JP5410431B2 (ja) 2007-09-27 2014-02-05 セントロ ナシオナル デ インベスティガシオネス オンコロヒカス（セエネイオ） イミダゾロチアジアゾール類のプロテインキナーゼ阻害剤としての使用
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2307425B1 (en) * 2008-07-29 2014-03-26 Merck Patent GmbH Imidazothiadiazoles derivatives
SI2414369T1 (sl) * 2009-04-02 2015-12-31 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Derivati imidazo(2,1-b)(1,3,4)tiadiazola
FR2945289A1 (fr) * 2009-05-11 2010-11-12 Sanofi Aventis Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique
WO2011036461A1 (en) 2009-09-24 2011-03-31 Centro Nacional De Investigaciones Oncόlogicas (Cnio) Fused imidazo [3, 2 - d] pyrazines as pi3 kinase inhibitors
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
CN102947302A (zh) 2010-02-18 2013-02-27 西班牙国家癌症研究中心 三唑并[4，5-b]吡啶衍生物
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
ES2986590T3 (es) 2010-06-14 2024-11-12 Scripps Research Inst Reprogramación de células hacia un nuevo destino
WO2012020217A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
WO2012020227A1 (en) 2010-08-11 2012-02-16 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
JP5918264B2 (ja) 2010-12-22 2016-05-18 アッヴィ・インコーポレイテッド Ｃ型肝炎阻害剤およびその使用
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
SG11201400681UA (en) 2011-05-19 2014-08-28 Ct Nac De Investigaciones Oncológicas Cnio Macrocyclic compounds as protein kinase inhibitors
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
EP2671885A1 (en) * 2012-06-05 2013-12-11 Ares Trading S.A. Imidazo-oxadiazole and Imidazo-thiadiazole derivatives
EP2682395A1 (en) 2012-07-04 2014-01-08 Laboratorios Del. Dr. Esteve, S.A. Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments
BR112015001201B1 (pt) * 2012-07-18 2022-02-22 University Of Notre Dame Du Lac Compostos anti-infecciosos 5,5-heteroaromáticos e composição
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
HUE055031T2 (hu) 2015-12-10 2021-10-28 Ptc Therapeutics Inc Módszerek Huntington-kór kezelésére
WO2017184520A1 (en) * 2016-04-18 2017-10-26 Vanderbilt University Substituted and fused 6-membered protease activated receptor 4 (par-4) antagonists
JP7376471B2 (ja) 2017-06-05 2023-11-08 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN112135815A (zh) 2018-03-27 2020-12-25 Ptc医疗公司 用于治疗亨廷顿氏病的化合物
MX2020014315A (es) 2018-06-27 2021-05-27 Ptc Therapeutics Inc Compuestos de heteroarilo para tratar la enfermedad de huntington.
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
ES2983003T3 (es) 2018-06-27 2024-10-21 Ptc Therapeutics Inc Compuestos heterocíclicos y heteroarílicos para el tratamiento de la enfermedad de Huntington
KR20210046649A (ko) * 2018-08-21 2021-04-28 교린 세이야꾸 가부시키 가이샤 이환식 헤테로방향환 유도체
EP4048678A4 (en) * 2019-10-21 2023-10-18 Novartis AG COMPOUNDS AND COMPOSITIONS FOR TREATING PARASITIC DISEASES
WO2023093700A1 (zh) * 2021-11-29 2023-06-01 中国海洋大学 咪唑并噻唑衍生物及其制备方法与应用
CN114195736B (zh) * 2021-12-30 2023-08-04 浙江闰土染料有限公司 2-氨基-5-溴-1,3,4-噻二唑的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1464259A (en) 1975-10-03 1977-02-09 Pfizer Ltd Imidazo-thiazole and -thiadiazole sulphonamides and their use as therapeutic agents
NO811630L (no) 1980-05-29 1981-11-30 Bayer Ag Imidazoazolalkensyreamider, nye mellomprodukter for deres fremstilling, deres fremstilling og deres anvendelse som legemiddel
DE3208437A1 (de) * 1982-03-09 1983-09-15 Bayer Ag, 5090 Leverkusen Imidazothiadiazolalkencarbonsaeureamide, neue zwischenprodukte zu ihrer herstellung, ihre herstellung und ihre verwendung in arzneimitteln
IT1269176B (it) 1994-01-11 1997-03-21 Isagro Srl Eterobicicli ad attivita' fungicida
AU7001396A (en) 1995-09-22 1997-04-09 Takeda Chemical Industries Ltd. Triazole compounds, their production and use
HK1052354A1 (zh) 2000-08-09 2003-09-11 Agouron Pharmaceuticals, Inc. 吡唑-噻唑化合物，包括它们的药物组分，和他们在抑制细胞周期蛋白依赖性激酶用途的方法
CA2364985A1 (en) * 2001-12-14 2003-06-14 John W. Gillard Imidazo(2,1-b)thiadiazole sulfonamides
US7268136B2 (en) 2002-12-18 2007-09-11 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
US20070112043A1 (en) 2003-06-13 2007-05-17 Jaquith James B Acylated and non-acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides, and uses thereof
US20060135571A1 (en) * 2003-06-13 2006-06-22 Jaquith James B Imidazo(2,1-b)-1,3,4-thiadiazole sulfoxides and sulfones
ES2441178T3 (es) 2005-06-01 2014-02-03 Ucb Pharma, S.A. Derivados de 2-oxo-1-pirrolidina, procedimientos para prepararlos y el uso terapéutico de los mismos sobre el sistema nervioso central
WO2007025090A2 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
US7750000B2 (en) * 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
KR20080080584A (ko) 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
BRPI0710133A2 (pt) * 2006-04-13 2012-10-30 Aegera Therapeutics Inc uso de compostos de imidazo[2,1-b]-1,3,4-tiadiazol-2-sulfonamida para tratar dor neuropática
WO2007136730A2 (en) 2006-05-21 2007-11-29 Steven Allen Carlson Systems and methods for hydrogen storage and generation
CN101037445A (zh) 2007-04-14 2007-09-19 西北师范大学 一种具有潜在生物活性的咪唑并[2，1－b]－1，3，4－噻二唑衍生物及其合成方法
AR066477A1 (es) 2007-05-09 2009-08-19 Novartis Ag Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido
EA200971077A1 (ru) * 2007-05-21 2010-04-30 ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. Гетероциклические модуляторы киназы
JP5410431B2 (ja) 2007-09-27 2014-02-05 セントロ ナシオナル デ インベスティガシオネス オンコロヒカス（セエネイオ） イミダゾロチアジアゾール類のプロテインキナーゼ阻害剤としての使用
EP2307425B1 (en) 2008-07-29 2014-03-26 Merck Patent GmbH Imidazothiadiazoles derivatives

Also Published As

Publication number Publication date
ES2548768T3 (es) 2015-10-20
HUE025976T2 (en) 2016-05-30
HRP20151128T1 (hr) 2015-11-20
PL2193133T3 (pl) 2016-01-29
WO2009040552A3 (en) 2009-05-22
EP2193133B1 (en) 2015-08-19
JP2010540508A (ja) 2010-12-24
CN101878219B (zh) 2014-04-02
CN101878219A (zh) 2010-11-03
CY1116882T1 (el) 2017-04-05
US8563550B2 (en) 2013-10-22
US20110190289A1 (en) 2011-08-04
DK2193133T3 (en) 2015-10-05
WO2009040552A2 (en) 2009-04-02
EP2193133A2 (en) 2010-06-09
JP5410431B2 (ja) 2014-02-05
PT2193133E (pt) 2015-10-22

Similar Documents

Publication Publication Date Title
HUS1900014I1 (hu) Proteinkináz inhibitorok
PL2193133T3 (pl) Imidazolotiadiazole do stosowania jako inhibitory kinazy białkowej
ZA201004243B (en) Benzofuropyrimidinones as protein kinase inhibitors
EP2200436A4 (en) SUBSTITUTED PYRIMIDINYLAMINE AS PROTEIN KINASENHEMMER
IL210073A0 (en) Protein kinase inhibitors
IL210069A0 (en) Protein kinase inhibitors
SI2201012T1 (sl) Derivati pirolo(2,3-D)pirimidina kot inhibitorji proteina kinaze B
PL2610256T3 (pl) Pochodne pirymidyny jako inhibitory kinaz białkowych
IL198487A0 (en) 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
ZA201004942B (en) Ptrrolopyrazine kinase inhibitors
IL198398A0 (en) 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
ZA201102423B (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
EP1993539A4 (en) THIAZOLONE AS A PI3 KINASE INHIBITOR
IL209729A0 (en) Novel phenylpyrazinones as kinase inhibitors
IL206394A0 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
EP2336123A4 (en) HETEROCYCLIC COMPOUND AS INHIBITOR OF PROTEIN KINASE
EP1993535A4 (en) THIAZOLONE AS A PI3 KINASE INHIBITOR
IL194491A0 (en) Thiazolyldihydroindazole derivatives as protein kinase inhibitors
EP1993536A4 (en) THIAZOLONES AS INHIBITORS OF P13-KINASES
EP1993537A4 (en) THIAZOLONES AS INHIBITORS OF P13-KINASES
EP1996191A4 (en) THIAZOLONE AS A PI3 KINASE INHIBITOR
ZA200810573B (en) Substituted 3-cyanopyridines as protein kinase inhibitors
IL197981A0 (en) Kinase inhibitors
EP1993538A4 (en) THIAZOLONES AS INHIBITORS OF P13-KINASES
GB0715470D0 (en) IKK- serine-threonine protein kinase inhibitors